Salidroside, also known as rhodioloside, is a natural product found in the Rhodiola genus of plants. As the most effective physiologically active substance in Rhodiola extracts, the content of salidroside is often used as a key reference for the medicinal standards and pricing of Rhodiola.

In recent years, with the continuous advancement of scientific research, salidroside has showcased a broad application potential across multiple fields, including food, dietary supplements, cosmetics, and medicine, due to its various benefits such as antioxidant, anti-aging, anti-hypoxia effects, and cardiovascular protection.

In the field of modern medicine, the importance of salidroside is evident. It has been widely applied in the research of cardiovascular and cerebrovascular diseases, such as atherosclerosis, stroke, and myocardial ischemia. With its natural, safe, and effective characteristics, salidroside offers new insights and directions for medical research. Products containing salidroside, whether dietary supplements or cosmetics, have won the favor of a wide range of consumers due to their exceptional quality and significant effects.

However, due to the status of Rhodiola as a nationally protected species, large-scale artificial cultivation has not yet been achieved, and the available natural resources are quite limited. Furthermore, the salidroside content in Rhodiola is relatively low, and the extraction process is complex and costly. These factors present significant challenges in the development and production of salidroside.

Currently, the development and production of salidroside primarily rely on two methods: natural extraction and chemical synthesis. However, both of these methods have notable disadvantages. In contrast, the method of bio-fermentation offers mild reaction conditions, simple processes, low costs, and high yields, making it more environmentally friendly and thus has been widely researched.

Against this backdrop, Henglu Biotech has adopted high-throughput screening and constructed a dual-channel synthesis pathway for E4P (an important precursor of salidroside), significantly enhancing the yield of yeast-synthesized tyrosol and salidroside, achieving large-scale production of salidroside with a purity of up to 99%.

Through the innovative application of high-throughput screening and the E4P dual-channel synthesis pathway, Henglu Biotech has become the first Chinese company in the world to successfully achieve large-scale production of salidroside using glucose. Looking ahead, Henglu will continue to uphold the spirit of originality and delve into the forefront of synthetic biotechnology, aiming to enhance the understanding of traditional Chinese medicine.